Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180011/S060

Eluvia Drug-Eluting Vascular Stent System

Boston Scientific Corp · Decision date Jan 30, 2026

FDA DECISIONP180011/S060

What did the FDA approve?

FDA records P180011/S060 as a supplement to PMA P180011, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 30, 2026.

FDA approval order statement

Approval for the post-approval labeling update to reflect the findings of the EMINENT post-approval study.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Jan 30, 2026
FDA change category
Labeling Change - PAS

FDA source record

Regulatory record facts

Identifier
P180011/S060
Regulatory pathway
PMA supplement
Product code
NIU
Decision code
APPR
Decision date
Jan 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, superficial femoral artery, drug-eluting.

Product code
NIU
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180011/S060 received

    Application receipt date recorded by FDA.

  2. P180011/S066 · Related supplement

    Eluvia Drug-Eluting Vascular Stent System

  3. P180011/S067 · Related supplement

    Eluvia Drug-Eluting Vascular Stent System

  4. P180011/S060 · FDA decision

    Normal 180 Day Track No User Fee

  5. P180011/S069 · Related supplement

    Eluvia Drug-Eluting Vascular Stent System

  6. P180011/S070 · Related supplement

    ELUVIA Drug-Eluting Vascular Stent System

Timeline entries are records held by MedtechLedger for P180011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180011

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA supplementAug 8, 2025FDA
Boston Scientific CorpPMA supplementOct 24, 2025FDA
Boston Scientific CorpPMA supplementAug 6, 2026FDA
Boston Scientific CorpPMA supplementAug 21, 2026FDA

Explore the linked device profile

Other records with product code NIU

Product / regulatory recordCompanyPathwayDecision dateSource
Cook Ireland, Ltd.PMA supplementNov 6, 2026FDA
Cook Ireland, Ltd.PMA supplementMar 25, 2026FDA
Cook Ireland, Ltd.PMA approvalNov 14, 2012FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
One Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records